Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To investigate whether volume of Gleason grade group 1 (GGG1) prostate cancer at prostate biopsy predicts unfavorable pathologic findings after radical prostatectomy (RP).
Methods: We retrospectively reviewed clinical and pathologic data from patients with biopsy-confirmed GGG1 prostate cancer and prostate-specific antigen < 20 ng/mL who underwent RP at our institution between May 2014 and May 2023. The percentage of positive biopsy cores (PPC) was defined as the number of cancer positive cores divided by the total number of cores at biopsy. The primary outcome was unfavorable pathology at RP, defined as ≥ GGG3, and/or pT3/4, and/or pN1. Gleason upgrading (≥ GGG2) and biochemical recurrence after RP were also evaluated. Multivariable logistic regression analyses were performed to assess the association between PPC and the risk of unfavorable pathology and Gleason upgrading.
Results: A total of 213 patients were analyzed. Median PPC was 17.0%. Unfavorable pathology was observed in 41.8%, while 53.1% had Gleason upgrading. PPC ≥ 17% was significantly associated with unfavorable pathology (odds ratio = 1.02; p = 0.030), but not with Gleason upgrading (odds ratio = 1.01; p = 0.189). The 5-year biochemical recurrence-free survival was 98.2% for PPC < 17% and 97.8% for PPC ≥ 17%, with no significant difference between the groups (log-rank p = 0.417).
Conclusion: Higher PPC was associated with unfavorable pathologic outcomes, but not with upgrading or recurrence, in biopsy-confirmed GGG1 prostate cancer patients treated with RP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-025-04641-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.
JAMA Netw Open
September 2025
Department of Urology, Center for Health Outcomes Research and Dissemination, University of Washington, Seattle.
Importance: Black individuals have a twofold higher rate of prostate cancer death in the US compared with the average population with prostate cancer. Few guidelines support race-conscious screening practices among at-risk Black individuals.
Objective: To examine structural factors that facilitate or impede access to prostate cancer screening among Black individuals in the US.
A new frontier in oncology: Understanding the landscape of cancer vaccines.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFDefining aging-associated factors that increase susceptibility to prostate cancer.
Endocr Relat Cancer
September 2025
Department of Molecular, Cell and Developmental Biology, University of California Los Angeles;Los Angeles, CA 90095.
Age is a major risk factor for a range of diseases including prostate cancer. Understanding how age influences the susceptibility of normal prostate epithelial cells to cancer initiation is complicated by the fact that aging affects all tissues in the body. Assessing how various aging mechanisms influence the prostate epithelium is a necessary step to determine the critical factors associated with aging that increase prostate cancer risk.
View Article and Find Full Text PDFGenomic Features of the methylosome protein MEP50 and its implication in Hormone Signaling and Cancer.
Endocr Connect
September 2025
Dysfunction of several WD40 family proteins causes diverse endocrine diseases. Until recently, MEP50, a WD40 protein, was considered a Gene of Unknown Significance (GUS) because no inherited diseases had been linked to its function. However, genetic inactivation of MEP50 in mouse models or somatic mutations in humans drive oncogenesis in several endocrine-related cancers, including those of the prostate, breast, and uterus.
View Article and Find Full Text PDFMulti-omic insights into mitochondrial dysfunction and prostatic disease: evidence from transcriptomics, proteomics, and methylomics.
Front Genet
August 2025
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: Prostatic diseases, consisting of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa), pose significant health challenges. While single-omics studies have provided valuable insights into the role of mitochondrial dysfunction in prostatic diseases, integrating multi-omics approaches is essential for uncovering disease mechanisms and identifying therapeutic targets.
Methods: A genome-wide meta-analysis was conducted for prostatic diseases using the genome-wide association studies (GWAS) data from FinnGen and UK Biobank.